Entrada Therapeutics TRDA Stock
Entrada Therapeutics Price Chart
Entrada Therapeutics TRDA Financial and Trading Overview
| Entrada Therapeutics stock price | 8.84 USD |
| Previous Close | 15.45 USD |
| Open | 15.17 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 14.02 - 16.24 USD |
| 52 Week Range | 6.65 - 24.38 USD |
| Volume | 119.94K USD |
| Avg. Volume | 52.06K USD |
| Market Cap | 479.03M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 1.68 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.5 USD |
TRDA Valuation Measures
| Enterprise Value | 117.49M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.1465516 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 18.964083 |
| Price/Book (mrq) | 2.082251 |
| Enterprise Value/Revenue | 4.651 |
| Enterprise Value/EBITDA | -1.49 |
Trading Information
Entrada Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 68.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 24.38 USD |
| 52 Week Low | 6.65 USD |
| 50-Day Moving Average | 13.6 USD |
| 200-Day Moving Average | 14.82 USD |
TRDA Share Statistics
| Avg. Volume (3 month) | 52.06K USD |
| Avg. Daily Volume (10-Days) | 77.96K USD |
| Shares Outstanding | 33.2M |
| Float | 12.71M |
| Short Ratio | 23.64 |
| % Held by Insiders | 15.07% |
| % Held by Institutions | 74.64% |
| Shares Short | 1.2M |
| Short % of Float | 6.29% |
| Short % of Shares Outstanding | 3.61% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -320.17% |
| Gross Margin | 70.76% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -12.75% |
| Return on Equity (ttm) | -31.40% |
Income Statement
| Revenue (ttm) | 25.26M USD |
| Revenue Per Share (ttm) | 0.8 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -78831000 USD |
| Net Income Avi to Common (ttm) | -79619000 USD |
| Diluted EPS (ttm) | -2.53 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 411.63M USD |
| Total Cash Per Share (mrq) | 12.4 USD |
| Total Debt (mrq) | 16.23M USD |
| Total Debt/Equity (mrq) | 7.07 USD |
| Current Ratio (mrq) | 2.941 |
| Book Value Per Share (mrq) | 6.93 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 130.6M USD |
| Levered Free Cash Flow (ttm) | 77.73M USD |
Profile of Entrada Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 6 Tide Street |
| ZIP | 02210 |
| Phone | 857 520 9158 |
| Website | https://www.entradatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 130 |
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Q&A For Entrada Therapeutics Stock
What is a current TRDA stock price?
Entrada Therapeutics TRDA stock price today per share is 8.84 USD.
How to purchase Entrada Therapeutics stock?
You can buy TRDA shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Entrada Therapeutics?
The stock symbol or ticker of Entrada Therapeutics is TRDA.
Which industry does the Entrada Therapeutics company belong to?
The Entrada Therapeutics industry is Biotechnology.
How many shares does Entrada Therapeutics have in circulation?
The max supply of Entrada Therapeutics shares is 38.1M.
What is Entrada Therapeutics Price to Earnings Ratio (PE Ratio)?
Entrada Therapeutics PE Ratio is 5.26190500 now.
What was Entrada Therapeutics earnings per share over the trailing 12 months (TTM)?
Entrada Therapeutics EPS is 1.68 USD over the trailing 12 months.
Which sector does the Entrada Therapeutics company belong to?
The Entrada Therapeutics sector is Healthcare.
Entrada Therapeutics TRDA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}